Form 4: Arcturus Therapeutics Executive Sells Shares Under 10b5-1 Trading Plan

Pad Chivukula, Chief Scientific Officer & COO of Arcturus Therapeutics, sold 17,435 shares of common stock at an average price of $35.02 on March 25, 2024, under a pre-arranged trading plan.

Summary

• On March 25, 2024, Pad Chivukula, the Chief Scientific Officer & COO of Arcturus Therapeutics Holdings Inc., sold 17,435 shares of the company's common stock.
• The sales were executed under a Rule 10b5-1 trading plan.
• The shares were sold at prices ranging from $35.00 to $35.045, with a weighted average price of $35.02 per share.
• Following the transaction, Chivukula directly owns 473,448 shares of Arcturus Therapeutics.
• The transaction was reported on a Form 4 filing with the Securities and Exchange Commission (SEC) on March 27, 2024.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to an executive stock sale under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment, but rather a routine transaction.

Industry Context

Sales by company executives are a normal part of corporate governance. The use of a 10b5-1 trading plan suggests the executive planned the sales in advance to avoid any accusations of insider trading.

Stakeholder Impact

• The stock sale could have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.

Key Dates